Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.66 |
| ▸ | DRD4 | P21917 | 1/20 | 0.66 |
| ▸ | DRD5 | P21918 | 1/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | HTR7 | P34969 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | HRH1 | P35367 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zicronapine SCHEMBL3801118 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AADRA2AADRA2B | |
| Zicronapine SCHEMBL904402 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AADRA2AADRA2B | |
| Zicronapine SCHEMBL29364267 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AADRA2AADRA2B | |
| Zicronapine SCHEMBL3801121 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AADRA2AADRA2B | |
| Zicronapine SCHEMBL933996 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AADRA2AADRA2B | |
| Zicronapine SCHEMBL3682563 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AADRA2AADRA2B | |
| Zicronapine SCHEMBL6061324 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AADRA2AADRA2B | |
| Zicronapine SCHEMBL2068746 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AADRA2AADRA2B | |
| Zicronapine SCHEMBL28595248 | 0.95 | DRD2 (0.90) | DRD2DRD1HTR1AADRA2AADRA2B | |
| Zicronapine SCHEMBL2069000 | 0.93 | DRD2 (0.86) | DRD2DRD1HTR1AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2720989-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2014-04-23 | — | — | EP | disclosed |
| US-8569499-B2 | Process for making trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine | H. LUNDBECK A/S (DK) | 2013-10-29 | — | — | US | disclosed |
| WO-2012176066-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2012-12-27 | — | — | WO | disclosed |
| US-8227607-B2 | Processes for 4-((1R,35)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a salt thereof | H. LUNDBECK A/S (DK) | 2012-07-24 | — | — | US | disclosed |
| US-8076342-B2 | Malonate salt of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and uses of same | H. LUNDBECK A/S (DK) | 2011-12-13 | — | — | US | disclosed |
| US-20110053957-A1 | MALONATE SALT OF 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-03-03 | — | — | US | disclosed |
| US-20100324291-A1 | PROCESSES FOR 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE OR A SALT THEREOF | H. LUNDBECK A/S (DK) | 2010-12-23 | — | — | US | disclosed |
| US-7767683-B2 | selective serotonin receptor antagonists used for the treatment of psychological disorders such as schizophrenia and bipolar disorders, as anxiolytic agents and antidepressants; improved water solubility; side effect reduction; | H. LUNDBECK A/S (DK) | 2010-08-03 | — | — | US | disclosed |
| US-20100069676-A1 | PROCESS FOR MAKING TRANS-1-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | H. LUNDBECK A/S (DK) | 2010-03-18 | — | — | US | disclosed |
| US-20090306092-A1 | METHOD FOR TREATING COGNITIVE DEFICITS | H. LUNDBECK A/S (DK) | 2009-12-10 | — | — | US | disclosed |
| US-20080153847-A1 | 2,2-Dimethylpiperazine derivative is reacted with 6-chloro-3-phenyl-indan-1-ol or 6-chloro-3-phenylindan-1-one; salt formation, precipitation, resolution, crystallization, amination, immobilization, catalysis; schizophrenia, psychoses, drug abuse, alcoholism; anxiolytic and antidepressants | H. LUNDBECK A/S (DK) | 2008-06-26 | — | — | US | disclosed |
| US-20060281759-A1 | selective serotonin receptor antagonists used for the treatment of psychological disorders such as schizophrenia and bipolar disorders, as anxiolytic agents and antidepressants; improved water solubility; side effect reduction; | H. LUNDBECK A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| EP-1658277-A1 | SUCCINATE AND MALONATE SALT OF TRANS-4-(IR,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND THE USE AS A MEDICAMENT | H. Lundbeck A/S (DK) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005016900-A1 | SUCCINATE AND MALONATE SALT OF TRANS-4-(IR,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND THE USE AS A MEDICAMENT | H. LUNDBECK A/S (DK) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069676-A1 | PROCESS FOR MAKING TRANS-1-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | CYP4Z1, CYP4F3, CYP1A1 | DRD2 472/4885DRD1 301/4885HTR1A 40/4885 |
| US-20100324291-A1 | PROCESSES FOR 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE OR A SALT THEREOF | CYP4Z1, HTR3C, HTR1D | DRD2 394/4885DRD1 321/4885HTR1A 7/4885 |
| US-20080153847-A1 | 2,2-Dimethylpiperazine derivative is reacted with 6-chloro-3-phenyl-indan-1-ol or 6-chloro-3-phenylindan-1-one; salt formation, precipitation, resolution, crystallization, amination, immobilization, catalysis; schizophrenia, psychoses, drug abuse, alcoholism; anxiolytic and antidepressants | ADH1A, ADH1C, ADH5 | DRD2 10/4885DRD1 14/4885HTR1A 46/4885 |
| US-20090306092-A1 | METHOD FOR TREATING COGNITIVE DEFICITS | CHAT, GRIK5, SLC6A2 | DRD2 320/4885DRD1 828/4885HTR1A 58/4885 |
| US-20060281759-A1 | selective serotonin receptor antagonists used for the treatment of psychological disorders such as schizophrenia and bipolar disorders, as anxiolytic agents and antidepressants; improved water solubility; side effect reduction; | HTR6, HTR1A, HTR2A | DRD2 70/4885DRD1 151/4885HTR1A 2/4885 |
| US-20110053957-A1 | MALONATE SALT OF 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND USES OF SAME | MAL2, ME1, SYNJ1 | DRD2 462/4885DRD1 489/4885HTR1A 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.